Randa Razzouk, MD
Pediatric Nephrology · Fort Worth, TXNPI 1558511071
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.9%), speaking fees and education — rather than concentrated in one kind of arrangement. 5 manufacturers reported payments, led by AstraZeneca at 51.7% of the total. Reporting peaked in 2020 at $150 and has fallen 96.3% since, to $6 in 2025.
Across 7 payments — averaging $48.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$177
- Sanofi$119
- Takeda Pharmaceuticals U.S.A., Inc.$21
- Alnylam Pharmaceuticals Inc.$19
- Travere Therapeutics, Inc.$6
Across 3 payments — averaging $34,204 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$103K
What the payments were for
- Speaking & faculty fees$15044%
- Food & beverage$16749%
- Education$257%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 2 | $177 |
| Sanofi | 1 | $119 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Travere Therapeutics, Inc. | 2 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$343 in reported general payments places this provider in the 55th percentile of 61 pediatric nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KaterziaAmlodipine Benzoate | 20 | $13,433 |
| Hydralazine Hcl | 27 | $7,781 |
| Sevelamer Carbonate | 19 | $4,573 |
| SpsSodium Polystyrene Sulfon/Sorb | 24 | $2,076 |
| Calcitriol | 30 | $1,004 |
| Labetalol Hcl | 27 | $881 |
| Propranolol Hcl | 12 | $731 |
| Felodipine ErFelodipine | 12 | $607 |
| Doxazosin Mesylate | 41 | $551 |
| Minoxidil | 12 | $44 |
| Prednisone | 15 | $40 |
| Pantoprazole Sodium | 15 | $33 |
| Amlodipine Besylate | 28 | $17 |
Paid to pharmacies, not to this prescriber.
Other pediatric nephrology in Fort Worth
- Robert GillespieFort Worth$11K
- Ketan PatelFort Worth$142
- Celina CepedaFort Worth$48
- Badreldin BedriFort Worth$18
- Amy BeckerCorpus Christi$77K
- Mini MichaelHouston$25K
- Rita SwinfordHouston$25K
- Ewa ElenbergHouston$16K
- Melissa CadnapaphornchaiSan Antonio$10K
- Samhar Al AkashCorpus Christi$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.